GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hinova Pharmaceuticals Inc (SHSE:688302) » Definitions » Liabilities-to-Assets

Hinova Pharmaceuticals (SHSE:688302) Liabilities-to-Assets : 0.11 (As of Mar. 2025)


View and export this data going back to 2022. Start your Free Trial

What is Hinova Pharmaceuticals Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Hinova Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2025 was ¥146.19 Mil. Hinova Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2025 was ¥1,309.87 Mil. Therefore, Hinova Pharmaceuticals's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2025 was 0.11.


Hinova Pharmaceuticals Liabilities-to-Assets Historical Data

The historical data trend for Hinova Pharmaceuticals's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hinova Pharmaceuticals Liabilities-to-Assets Chart

Hinova Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Liabilities-to-Assets
Get a 7-Day Free Trial 0.17 0.20 0.09 0.08 0.12

Hinova Pharmaceuticals Quarterly Data
Dec18 Dec19 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Liabilities-to-Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.08 0.12 0.12 0.12 0.11

Competitive Comparison of Hinova Pharmaceuticals's Liabilities-to-Assets

For the Biotechnology subindustry, Hinova Pharmaceuticals's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hinova Pharmaceuticals's Liabilities-to-Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hinova Pharmaceuticals's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Hinova Pharmaceuticals's Liabilities-to-Assets falls into.


;
;

Hinova Pharmaceuticals Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Hinova Pharmaceuticals's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2024 is calculated as:

Liabilities-to-Assets (A: Dec. 2024 )=Total Liabilities/Total Assets
=169.335/1361.58
=0.12

Hinova Pharmaceuticals's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2025 is calculated as

Liabilities-to-Assets (Q: Mar. 2025 )=Total Liabilities/Total Assets
=146.194/1309.873
=0.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hinova Pharmaceuticals  (SHSE:688302) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


Hinova Pharmaceuticals Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of Hinova Pharmaceuticals's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Hinova Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
No. 5 Keyuan South Road, No. 2 and 3, 4th Floor, Building 1, Rongyao Building, High-tech Zone, Sichuan Province, Chengdu, CHN, 610041
Hinova Pharmaceuticals Inc is an international drug company based on technology platforms such as deuterium and PROTAC, aiming to develop Best-in-class and First-in-class drugs with major clinical needs. The company focuses on the research and development of drugs in therapeutic areas such as oncology and metabolic diseases, focusing on providing safe, effective and affordable drugs for patients, and is committed to the development and production of drugs with global rights and interests.

Hinova Pharmaceuticals Headlines

No Headlines